This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
BACKGROUND: Patients receiving mechanical ventilation often require airway clearance and inhaled therapies. Intrapulmonary percussive ventilation (IPV) combines a high-frequency percussive ventilator with a jet nebulizer. Data on aerosol delivery efficiency of the device are scarce. We evaluated albuterol delivery efficiency while using an IPV in-line adapter under different conditions.
METHODS: A pediatric lung model of invasive mechanical ventilation was used. The following independent variables were evaluated: lung condition (normal vs ARDS), ventilator mode (adaptive pressure ventilation vs pressure control), percent opening of adapter (0% vs 25% vs 50%), IPV driving pressure (25 psi vs 40 psi), IPV percussion setting (easy vs hard), and endotracheal tube (ETT) size (3.5 mm vs 5.5 mm). Albuterol delivery efficiency (mass captured in the filter expressed as percentage of loading dose) was selected as the dependent variable. Albuterol was captured on a filter at the tip of the ETT and quantified via spectrophotometry (276 nm).
RESULTS: Albuterol delivery efficiency ranged from 0–2.89%. Median (interquartile range) and 95% CI around the median were 0.54% (0.37–1.00) and 0.50–0.63%, respectively. The coefficient of determination (R2) for the model including all variables was 0.363. The 2 main contributors were percent of adapter opening (R2 0.30) and IPV setting (R2 0.039).
CONCLUSIONS: Albuterol delivery during invasive mechanical ventilation via in-line IPV in a pediatric lung model was inefficient. Alternative methods of delivering bronchodilators and other inhaled medications should be considered when IPV is used.
- intrapulmonary percussive ventilation
- airway clearance
- aerosol
- lung deposition
- in-line adapter
- lung model
- pediatric
- albuterol
- nebulizer
Footnotes
- Correspondence: Ariel Berlinski MD FAARC, University of Arkansas for Medical Sciences, 1 Children's Way, Slot 512–17, Little Rock, AR 72202. E-mail: BerlinskiAriel{at}uams.edu
Dr Berlinski discloses relationships with Cystic Fibrosis Foundation, National Institutes of Health, Therapeutic Development Network, Trudell Medical International, Vertex, UpToDate, Hollo Medical, and the International Pharmaceutical Aerosol Consortium on Regulation and Science. Ms Willis is a section editor for Respiratory Care.
Ms Willis presented a version of this paper as an Editor's Choice abstract at AARC Congress 2022, held November 9–12, 2022, in New Orleans, Louisiana.
Ms Willis was partially funded by Arkansas Children's Research Institute through the Arkansas Biosciences Institute Nursing and Allied Health Research Grant (GR037138 3981).
- Copyright © 2024 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.